Increased expression of PD-1, PD-L1 and CTLA-4 were found in stromal/immune cells of group II as compared to Group I. Expression of these immune markers showed significant correlation with poor tumor differentiation, tumor invasion and patient outcome (p<0.05). This evidence concerns the gene PDCD1 and neoplasm.